CVS Group plc: history, ownership, mission, how it works & makes money

From its founding in 1999 in Diss, CVS Group plc has evolved into a publicly traded veterinary services powerhouse (AIM: CVSG) that in recent years has sharpened its focus through strategic divestments and targeted acquisitions - notably exiting loss-making Netherlands and Ireland operations in May 2024 and selling its Crematoria business in April 2025 for £42 million (a 10x adjusted EBITDA multiple) - while accelerating international expansion in Australia with seven practices (15 sites) acquired for £29.2 million in the year to 30 June 2025 and growing to 30 practices across 45 sites by October 2025; the group now employs roughly 8,850-9,000 people, including about 2,400 veterinary surgeons and 3,300 nurses, is led by CEO Richard William Fairman with Robin Alfonso as CFO and Claire Slater as COO, and reported a 5.4% revenue increase to £673.2 million for continuing operations (adjusted EBITDA circa £134 million) while investing £16.8 million in H1 2025 on refurbishments and technology, growing Healthy Pet Club membership from 507,000 at 31 Dec 2024 to 520,000 by 31 Oct 2025, targeting over £50 million pa of overseas acquisitions (with £33 million spent in FY2025) and aiming to reduce leverage to approximately 1.2x by 30 June 2025 - a fast-moving mix of clinical services, laboratories, online retail (Animed Direct) and subscription healthcare that drives the company's revenues and acquisition-fueled growth plans.

CVS Group plc (CVSG.L): Intro

• Founded in 1999 and headquartered in Diss, United Kingdom.
• Early growth driven by consolidation of veterinary practices and complementary pet-related services across the UK.
• 2010s-2020s: expansion through both organic growth and targeted acquisitions, diversification into crematoria, imaging and pathology services, and international markets.
• May 2024: divested loss-making operations in the Netherlands and the Republic of Ireland to refocus on higher-margin markets.
• April 2025: sold Crematoria operations for £42.0 million (a c.10x adjusted EBITDA multiple) to strengthen the balance sheet.
• FY 2025 (to 30 June): acquired seven Australian practices (15 sites) for £29.2 million; by October 2025 the Australian portfolio expanded to 30 practices with 45 sites.

• Publicly listed on the London Stock Exchange (ticker: CVSG.L).
• Operates as a group holding company with multiple operating subsidiaries across veterinary services, pet healthcare, diagnostics and ancillary services.
• Shareholder base comprises institutional investors, UK retail holders and management; structure supports centralized M&A and capital allocation decisions.

• Corporate purpose centers on delivering high-quality veterinary care and pet wellbeing services while achieving sustainable, profitable growth.
• For a formal statement: Mission Statement, Vision, & Core Values (2026) of CVS Group plc.

• Core service lines: primary-care veterinary practices, specialist clinics, diagnostic services (imaging & pathology), and ancillary services (pet crematoria historically, retail and pet care products).
• Market approach: roll-up model combining local clinical expertise with centralized support (procurement, IT, HR, compliance, and capital investment) to drive clinical quality and margin improvement.
• Geographic focus: historically UK-centric with selective international expansion (notably Australia); exited underperforming continental European operations in 2024.
• Growth levers: acquisitions (clinical assets and groups), network scale benefits, premium service offerings, and selective divestments to recycle capital.

• Clinical revenue: fees for consultations, surgeries, diagnostics, and specialist treatments - the largest recurring revenue stream.
• Diagnostics and pathology: higher-margin testing and imaging services billed to clinics and external customers.
• Retail and consumables: sales of prescription diets, medicines and pet products in-clinic and online.
• Professional services and referral income from specialist practices.
• Property and service contracts: income from serviced clinic sites and franchise/managed practice arrangements in some markets.
• Selective asset disposals (e.g., Crematoria sale) used to optimize capital structure and fund higher-return investments.

• Prioritises reinvestment into higher-return clinical assets and markets (e.g., Australia expansion).
• Uses disposals to de-lever and to fund bolt-on acquisitions (illustrated by Crematoria sale funding redeployment).
• Targets margin improvement through centralised procurement, scale efficiencies and service mix shift toward diagnostics and specialist care.

CVS Group plc (CVSG.L): History

• Listed on London Stock Exchange AIM under ticker CVSG.
• Public float with institutional and retail shareholders; progressive acquisition-led growth model.
• Leadership driving strategy:
  • Chief Executive Officer: Richard William Fairman
  • Chief Financial Officer: Robin Alfonso
  • Chief Operating Officer: Claire Slater

• Mission: Deliver accessible, high-quality veterinary care and diagnostics while scaling specialty and preventative services to improve animal health and client experience.
• How it works:
  • Operate a network of veterinary clinics and referral hospitals providing consultations, surgery, diagnostics and inpatient care.
  • Provide diagnostic laboratory services and pathology to support clinical decision-making and external customers.
  • Integrate digital health, preventive-care plans and pharmacy services to increase recurring revenue and client retention.
• How it makes money:
  • Clinical services (consultations, surgeries, inpatient care) - primary revenue driver.
  • Diagnostics and laboratory services - margins from centralized testing and specialist assays.
  • Pharmacy and consumables - retail and prescription fulfilment across clinics and online.
  • Preventive-care plans and subscription services - recurring revenue stream and lifetime client value enhancement.

CVS Group plc (CVSG.L): Ownership Structure

• Approximately 460 veterinary practices, including specialist referral hospitals and out-of-hours sites.
• Laboratories and crematoria supporting clinical workflows and end-of-life services.
• Online retail business complementing in-clinic retail and recurring care programmes.
• About 9,000 employees: ~2,400 veterinary surgeons and ~3,300 veterinary nurses.

• 507,000 members as of 31 December 2024.
• Provides predictable recurring revenue and drives clinical visit frequency and retail sales.

• £16.8m invested in H1 2025 for practice refurbishment, relocations, clinical equipment and technology.
• Enhanced employer pension contributions (matching up to 6%), resulting in 1,400+ employees increasing their contributions.
• Partnership with Employers Network for Equality & Inclusion (ENEI) to support diversity and inclusion initiatives.

• Clinical services: consultations, surgeries, specialist referrals and out-of-hours care.
• Preventative care memberships: Healthy Pet Club generates recurring subscription income and increases lifetime customer value.
• Pharmacy and retail: in-practice and online sales of food, medicines and accessories.
• Laboratory and diagnostic services supporting clinical decision-making and external contracts.
• Crematoria and end-of-life services providing specialist fee-based revenue.

CVS Group plc (CVSG.L): Mission and Values

• Veterinary Practices - ~460 sites, including primary-care clinics, specialist referral hospitals and out‑of‑hours centres providing consultations, surgery, preventive care and specialist treatments.
• Laboratories & Crematoria - in‑house diagnostic labs for bloodwork, imaging and pathology plus cremation/end‑of‑life services that support clinical decision‑making and provide a revenue stream from ancillary services.
• Online Retail (Animed Direct) - e‑commerce channel selling prescription and OTC medicines, pet foods, accessories and repeat prescription services to owners nationwide.

• Practices: approximately 460 sites.
• Workforce: around 9,000 employees.
• Clinical headcount: ~2,400 veterinary surgeons and ~3,300 veterinary nurses.
• Capital investment: £16.8 million invested in H1 2025 across practice refurbishments, relocations, clinical equipment and technology.

• Clinical services - consultations, diagnostics, surgery, dental, imaging, specialist referral work and emergency/out‑of‑hours care billed to clients or insurers.
• Pharmacy and repeat prescriptions - in‑practice dispense and fulfilment via Animed Direct for both prescriptions and OTC products.
• Retail sales - food, bedding, accessories and preventive products sold in clinics and online.
• Laboratory and diagnostic services - fee‑for‑service testing for internal and external clients.
• Crematoria and end‑of‑life services - paid services associated with euthanasia and aftercare.
• M&A and network growth - acquisitions of independent practices to scale revenue and spread fixed costs across a larger network.

• Technology - clinical practice management systems, online repeat prescription platforms and telemedicine to increase throughput and owner engagement.
• Practice upgrades - targeted refurbishments and relocations to modernise sites and improve utilisation.
• Training and retention - investment in clinical training and recruitment to retain vets and nurses amid sector shortages.
• Vertical integration - linking clinics, labs and e‑commerce to capture more of the customer lifecycle and enhance margins.

CVS Group plc (CVSG.L): How It Works

• Primary clinical services: consultations, routine surgeries, diagnostics, dental work, and 24/7 emergency care delivered through a network of veterinary practices and referral hospitals.
• Laboratory services: in-house and third-party diagnostic testing that supports practices and external customers (pathology, imaging, microbiology, PCR and specialty testing).
• Online retail (Animed Direct): e-commerce sales of prescription and non-prescription medicines, pet nutrition and supplies to both consumers and clinics.
• Preventative-care memberships (Healthy Pet Club): recurring subscription income for vaccination, parasite control and wellness bundles.
• End-of-life services (crematoria): historically provided cremation and related services; note the crematoria business was divested in April 2025 for £42 million to sharpen focus on core segments.

• Fee-for-service clinical billing: face-to-face consultations, surgical procedures and inpatient care billed per event or package.
• Diagnostics-as-a-service: tests ordered by vets or directly by customers, billed on a per-test basis with margin from in-house processing.
• Retail margin and subscription revenue: animed direct generates gross margin on product sales; Healthy Pet Club provides recurring membership fees and improves lifetime value.
• Cross-sell and referral flows: clinics promote Animed Direct and Healthy Pet Club; laboratories drive repeat clinic visits; digital channels increase retention.

• Same-practice revenue growth: driven by case mix, fee inflation (average pricing per consultation/procedure) and increased preventive care uptake.
• Practice roll-up and M&A: inorganic growth via acquisitions expands clinic count and geographic footprint, increasing scale for procurement and cross-sell.
• Digital adoption: shifting prescription fulfilment to Animed Direct increases unit economics and lifetime value while lowering per-order cost.
• Membership penetration: Healthy Pet Club membership take-up raises recurring revenue and reduces seasonality.
• Laboratory capacity utilisation: boosting test volumes improves fixed-cost absorption and margins.

• Sale of crematoria business: completed April 2025 for £42.0 million, reallocating capital to core veterinary and diagnostic operations.
• Membership scale: Healthy Pet Club has been a multi-hundred-thousand-member programme contributing steady recurring fees and higher retention (membership scale supports the ~6% illustrative revenue share above).
• Animed Direct growth: e-commerce channel represents a significant and growing portion of retail turnover, improving online repeat purchase rates and prescription adherence.

CVS Group plc (CVSG.L): How It Makes Money

Market Position & Future Outlook

• FY ending 30 June 2025 revenue from continuing operations: £673.2m (up 5.4% year-on-year).
• Planned overseas acquisition investment: >£50m p.a.; £33m invested in FY2025.
• Leverage ratio improvement: 1.66x (June 2024) → ~1.2x (expected June 30, 2025).
• Healthy Pet Club membership: 520,000 members as of 31 Oct 2025, supporting recurring revenue and customer retention.
• Strong pipeline in Australia, signifying further regional growth potential.
• Ongoing investment in clinical quality and infrastructure: £11.5m invested YTD in practice refurbishment, relocations, clinical equipment and technology.

Revenue drivers and mechanics

• Clinical services: consultations, surgery, diagnostics and specialist referrals-high-margin and repeat-driven.
• Prescription and preventive healthcare: recurring sales through retail and subscription channels (Healthy Pet Club fosters loyalty and recurring income).
• Acquisitions: bolt-on practice purchases expand geographic reach and consolidate local market share, improving scale economics.
• Facilities & tech investment: refurbishment and equipment spending enhance throughput, case mix and pricing power.

Further reading: Mission Statement, Vision, & Core Values (2026) of CVS Group plc.